Nicotinamide Riboside Restores NAD+ Levels and Improves Metabolism in Diastolic Heart Failure: Preclinical Findings

Synopsis

Heart failure with left ventricular diastolic dysfunction is a growing health problem worldwide. This study looked at levels of NAD+, a key metabolic cofactor, in the hearts of patients with systolic and diastolic heart failure, as well as in a mouse model of heart failure with preserved ejection fraction. Researchers found that NAD+ and the enzyme nicotinamide phosphoribosyltransferase were significantly reduced in human diastolic heart failure hearts. Treatment with nicotinamide riboside (NR) restored NAD+ levels and, in mice, improved both metabolic and antioxidant function. These findings suggest that boosting NAD+ with NR could be a promising strategy for managing diastolic heart failure.

Journal

JACC: Basic to Translational Science